Boronic Acid Salts Useful in Parenteral Formulations
OwnerDavid Jonathan MADGE, Mark Dolman +4inventors
InventorsDavid Jonathan MADGE, Mark Dolman, Sophie Marie Combe-Marzelle, John Joseph Deadman, Anthony James Kennedy, Sanjay Kumar Kakkar
Life of this patent
Estimating the term…
Abstract
Salts of a peptide boronic acid drug, for example of Cbz-(R)-Phe-(S)—Pro-(R)-Mpg-B(OH)2. The counter-ion to the boronate may be an alkali metal or derived from a strongly basic organic nitrogen-containing compound.
Claims29
A parenteral pharmaceutical formulation comprising a therapeutically effective amount of a pharmaceutically acceptable base addition salt of a boronic acid of formula (I):
- wherein
- Y comprises a hydrophobic moiety which, together with the aminoboronic acid residue —NHCH(R9)—B(OH)2, has affinity for the substrate binding site of thrombin;
- and
- R9 is a straight chain alkyl group interrupted by one or more ether linkages and in which the total number of oxygen and carbon atoms is 3, 4, 5 or 6 or R9 is —(CH2)m—W where m is from 2, 3, 4 or 5 and W is —H or halogen.
A formulation in parenteral dosage form comprising a therapeutically effective amount of a pharmaceutically acceptable base addition salt of a boronic acid of formula (II):
- where:
- X is H or an amino-protecting group;
- aa1 is an amino acid residue having a hydrocarbyl side chain containing no more than 20 carbon atoms and comprising at least one cyclic group having up to 13 carbon atoms;
- aa2 is an imino acid residue having from 4 to 6 ring members;
- R1 is a group of the formula —(CH2)s-Z, where s is 2, 3 or 4 and Z is —OH, —OMe, —OEt or halogen.
A pharmaceutical product comprising a sealed container containing in the form of a finely divided solid, ready for reconstitution to form a liquid parenteral formulation, a therapeutically effective amount of a boronate salt which consists essentially of a single pharmaceutically acceptable base addition salt of a boronic add formula (II):
- where:
- X is H or an amino-protecting group;
- aa1 is an amino acid residue of R-configuration having a hydrocarbyl side chain containing no more than 20 carbon atoms and comprising at least one cyclic group having up to 13 carbon atoms;
- aa2 is an imino acid residue of S-configuration having from 4 to 6 ring members;
- C* is a chiral centre of R-configuration;
- and
- R1 is a group of the formula —(CH2)s-Z, where s is 2, 3 or 4 and Z is —OH, —OMe, —OEt or halogen.
A pharmaceutical formulation adapted for parenteral administration, whether directly or after combining with a liquid, and comprising
- a) a first species selected from a boronic acid of formula (I), and boronate ions of said boronic acid and equilibrium forms of said boronic acid and said boronate ions:
- wherein
- Y comprises a hydrophobic moiety which, together with the aminoboronic acid residue —NHCH(R9)—B(OH)2, has affinity for the substrate binding site of thrombin;
- and
- R9 is a straight chain alkyl group interrupted by one or more ether linkages and in which the total number of oxygen and carbon atoms is 3, 4, 5 or 6 or R9 is —(CH2)m—W where m is from 2, 3, 4 or 5 and W is —OH or halogen;
- and
- (b) a second species selected from pharmaceutically acceptable metal ions, said metal ions having a valency of n, lysine, arginine and aminosugars,
- wherein the formulation has an observed stoichiometry of first to second species essentially consistent with a notional stoichiometry of 1:1 when the second species is a metal ion with a valency of 1 or is lysine, arginine or an aminosugar, or an observed stoichiometry of n:1 when the second species is a metal ion with a valency of greater than 1.
A medicament adapted for parenteral administration and comprising a therapeutically effective amount of a pharmaceutically acceptable base addition salt of a boronic acid which is a selective thrombin Inhibitor and has a neutral aminoboronic acid residue capable of binding to the thrombin S1 subsite linked through a peptide linkage to a hydrophobic moiety capable of binding to the thrombin S2 and 53 subsites, the salt comprising a cation having a valency n and having an observed stoichiometry consistent with a notional stoichiometry (boronic acid:cation) of n:
- 1.
Dependencies are inferred from the claim text.